1094 Favorable preclinical efficacy and safety profile of AVB-001 a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first in human clinical developmentGuillaume Carmona, Omid Veiseh, Amanda Nash et al.|Regular and Young Investigator Award Abstracts|2022Cited by 0
1045 Overcoming immunosuppressive tumors by stimulating the adaptive and innate immune systemsGuillaume Carmona, Omid Veiseh, Amanda Nash et al.|Regular and Young Investigator Award Abstracts|2023Cited by 0
Supplementary Figure S8 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian CarcinomaHelen Clark, Shannon N. Westin, Samira Aghlara-Fotovat et al.|Unknown|2026Cited by 0
Supplementary Figure S2 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian CarcinomaHelen Clark, Shannon N. Westin, Samira Aghlara-Fotovat et al.|Unknown|2026Cited by 0
Supplementary Figure S1 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian CarcinomaHelen Clark, Shannon N. Westin, Samira Aghlara-Fotovat et al.|Unknown|2026Cited by 0